Algorithm for codevelopment of new drug-predictive biomarker combinations: accounting for inter- and intrapatient tumor heterogeneity.
作者信息
Gandara David R, Li Tianhong, Lara Primo N, Mack Philip C, Kelly Karen, Miyamoto Suzanne, Goodwin Neal, Beckett Laurel, Redman Mary W
机构信息
University of California Davis Cancer Center, Sacramento, CA, USA.
出版信息
Clin Lung Cancer. 2012 Sep;13(5):321-5. doi: 10.1016/j.cllc.2012.05.004. Epub 2012 Jun 6.
Abstract
摘要
相似文献
1
Algorithm for codevelopment of new drug-predictive biomarker combinations: accounting for inter- and intrapatient tumor heterogeneity.新药预测性生物标志物组合的共同开发算法：考虑患者间和患者内肿瘤异质性。
Clin Lung Cancer. 2012 Sep;13(5):321-5. doi: 10.1016/j.cllc.2012.05.004. Epub 2012 Jun 6.
2
Biomarkers of Bad Biology: Curse or a Blessing?不良生物学的生物标志物：祸还是福？
Ann Surg Oncol. 2019 Feb;26(2):318-320. doi: 10.1245/s10434-018-07105-w. Epub 2018 Dec 11.
3
The Future of Precision Oncology for the Treatment of Solid Tumors.实体瘤治疗中精准肿瘤学的未来。
Clin Pharmacol Ther. 2020 Sep;108(3):416-418. doi: 10.1002/cpt.1739. Epub 2020 Jan 25.
4
Implications of intratumour heterogeneity for treatment stratification.肿瘤内异质性对治疗分层的影响。
J Pathol. 2014 Jan;232(2):264-73. doi: 10.1002/path.4270.
5
Pharmacogenomic landscape of patient-derived tumor cells informs precision oncology therapy.患者来源肿瘤细胞的药物基因组学全景分析为精准肿瘤治疗提供信息。
Nat Genet. 2018 Oct;50(10):1399-1411. doi: 10.1038/s41588-018-0209-6. Epub 2018 Sep 27.
6
Point: The Imprecise Pursuit of Precision Medicine: Are Biomarkers to Blame?观点：对精准医学的不精确追求：生物标志物该为此负责吗？
J Natl Compr Canc Netw. 2017 Jul;15(7):859-862. doi: 10.6004/jnccn/2017.0126.
7
Is Precision Medicine an Oxymoron?精准医学是一种矛盾修辞法吗？
JAMA Oncol. 2019 Feb 1;5(2):142-143. doi: 10.1001/jamaoncol.2018.5099.
8
New ESMO scale ranks mutations as cancer medicine targets.新的欧洲肿瘤内科学会（ESMO）量表将突变列为癌症药物靶点。
Lancet Oncol. 2018 Oct;19(10):e513. doi: 10.1016/S1470-2045(18)30664-8. Epub 2018 Aug 31.
9
Maurie Markman on the Groundbreaking TAPUR Trial.莫里·马克曼谈开创性的TAPUR试验。
Oncology (Williston Park). 2017 Mar 15;31(3):158, 168.
10
Giving Up on Precision Oncology? Not So Fast!放弃精准肿瘤学？没那么快！
Clin Transl Sci. 2017 May;10(3):128-129. doi: 10.1111/cts.12457. Epub 2017 Feb 21.
引用本文的文献
1
Clinicopathological Features, Epidermal Growth Factor Receptor (EGFR) Mutations and Anaplastic Lymphoma Kinase (ALK) Rearrangement-Based Survival of Patients With Advanced Non-small Cell Lung Cancer in a Tertiary Care Setting.三级医疗环境中晚期非小细胞肺癌患者的临床病理特征、表皮生长因子受体（EGFR）突变及间变性淋巴瘤激酶（ALK）重排与生存情况
Cureus. 2024 Dec 23;16(12):e76257. doi: 10.7759/cureus.76257. eCollection 2024 Dec.
2
Radiomics nomogram for the prediction of Ki-67 index in advanced non-small cell lung cancer based on dual-phase enhanced computed tomography.基于双期增强 CT 的放射组学列线图预测晚期非小细胞肺癌 Ki-67 指数
J Cancer Res Clin Oncol. 2023 Sep;149(11):9301-9315. doi: 10.1007/s00432-023-04856-2. Epub 2023 May 19.
3
Biospecimen Digital Twins: Moving from a "High Quality" to a "Fit-for-Purpose" Concept in the Era of Omics Sciences.生物样本数字孪生：在组学时代从“高质量”到“适用目的”概念的转变。
Cancer Genomics Proteomics. 2023 May-Jun;20(3):211-221. doi: 10.21873/cgp.20376.
4
Analysis of the relationship between Ki-67 expression and chemotherapy and prognosis in advanced non-small cell lung cancer.晚期非小细胞肺癌中Ki-67表达与化疗及预后的关系分析
Transl Cancer Res. 2020 May;9(5):3491-3498. doi: 10.21037/tcr.2020.03.72.
5
Current and Prospective Protein Biomarkers of Lung Cancer.肺癌的当前及潜在蛋白质生物标志物
Cancers (Basel). 2017 Nov 13;9(11):155. doi: 10.3390/cancers9110155.
6
Pemetrexed/Carboplatin/Bevacizumab followed by Maintenance Pemetrexed/Bevacizumab in Hispanic Patients with Non-Squamous Non-Small Cell Lung Cancer: Outcomes according to Thymidylate Synthase Expression.培美曲塞/卡铂/贝伐单抗序贯培美曲塞/贝伐单抗维持治疗西班牙裔非鳞状非小细胞肺癌患者：根据胸苷酸合成酶表达的结果
PLoS One. 2016 May 18;11(5):e0154293. doi: 10.1371/journal.pone.0154293. eCollection 2016.
7
Bridging tumor genomics to patient outcomes through an integrated patient-derived xenograft platform.通过整合患者来源的异种移植平台将肿瘤基因组学与患者预后联系起来。
Clin Lung Cancer. 2015 May;16(3):165-72. doi: 10.1016/j.cllc.2015.03.001. Epub 2015 Mar 18.
8
Influence of chemotherapy on EGFR mutation status.化疗对 EGFR 突变状态的影响。
Transl Lung Cancer Res. 2013 Dec;2(6):442-4. doi: 10.3978/j.issn.2218-6751.2013.10.12.
9
[Advances on driver oncogenes of non-small cell lung cancer].[非小细胞肺癌驱动癌基因的研究进展]
Zhongguo Fei Ai Za Zhi. 2015 Jan;18(1):42-7. doi: 10.3779/j.issn.1009-3419.2015.01.07.
10
Higher susceptibility of NOD/LtSz-scid Il2rg (-/-) NSG mice to xenotransplanted lung cancer cell lines.NOD/LtSz-scid Il2rg(-/-) NSG 小鼠对异种移植肺癌细胞系更敏感。
Cancer Manag Res. 2014 Oct 21;6:431-6. doi: 10.2147/CMAR.S71185. eCollection 2014.
本文引用的文献
1
Mechanisms of resistance to crizotinib in patients with ALK gene rearranged non-small cell lung cancer.ALK 基因重排非小细胞肺癌患者对克唑替尼耐药的机制。
Clin Cancer Res. 2012 Mar 1;18(5):1472-82. doi: 10.1158/1078-0432.CCR-11-2906. Epub 2012 Jan 10.
2
Personalized oncology through integrative high-throughput sequencing: a pilot study.通过整合高通量测序进行个体化肿瘤学：一项初步研究。
Sci Transl Med. 2011 Nov 30;3(111):111ra121. doi: 10.1126/scitranslmed.3003161.
3
Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis.克唑替尼治疗携带 ALK 基因重排的晚期非小细胞肺癌患者的总生存影响：一项回顾性分析。
Lancet Oncol. 2011 Oct;12(11):1004-12. doi: 10.1016/S1470-2045(11)70232-7. Epub 2011 Sep 18.
4
Evolutionary dynamics of intratumor heterogeneity.肿瘤内异质性的进化动态。
PLoS One. 2011 Mar 30;6(3):e17866. doi: 10.1371/journal.pone.0017866.
5
Implications of personalized medicine--perspective from a cancer center.个性化医学的意义——癌症中心的观点。
Nat Rev Clin Oncol. 2011 Mar;8(3):177-83. doi: 10.1038/nrclinonc.2010.222.
6
The mutation spectrum revealed by paired genome sequences from a lung cancer patient.配对肺癌患者基因组序列揭示的突变谱。
Nature. 2010 May 27;465(7297):473-7. doi: 10.1038/nature09004.
7
Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma.吉非替尼或卡铂-紫杉醇用于治疗肺腺癌。
N Engl J Med. 2009 Sep 3;361(10):947-57. doi: 10.1056/NEJMoa0810699. Epub 2009 Aug 19.
8
Clinical trial designs for predictive biomarker validation: theoretical considerations and practical challenges.预测性生物标志物验证的临床试验设计：理论考量与实际挑战。
J Clin Oncol. 2009 Aug 20;27(24):4027-34. doi: 10.1200/JCO.2009.22.3701. Epub 2009 Jul 13.
9
Individualizing therapy for non-small-cell lung cancer: a paradigm shift from empiric to integrated decision-making.非小细胞肺癌的个体化治疗：从经验性决策到综合决策的模式转变。
Clin Lung Cancer. 2009 May;10(3):148-50. doi: 10.3816/CLC.2009.n.020.
10
Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial.西妥昔单抗联合化疗治疗晚期非小细胞肺癌患者（FLEX）：一项开放标签的随机III期试验。
Lancet. 2009 May 2;373(9674):1525-31. doi: 10.1016/S0140-6736(09)60569-9.
Zotero 插件